A new treatment for diffuse large B-cell lymphoma
A Next-Generation Nucleoside Prodrug for Diffuse Large B-Cell Lymphoma
This study is testing a new treatment for diffuse large B-cell lymphoma (DLBCL) using a special compound that has shown promise in lab tests, and it's designed for patients who haven't had success with current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11001979 on NIH RePORTER |
What this research studies
This research focuses on developing a novel nucleoside prodrug aimed at treating diffuse large B-cell lymphoma (DLBCL), a common type of blood cancer. The approach involves using a compound called 4’-ethynyl-deoxycytidine (EdC), which has shown high effectiveness in pre-clinical tests against DLBCL cells. By inducing replicative stress and inhibiting DNA damage response, EdC aims to provide a new therapeutic option for patients who have not responded to existing treatments. The research includes extensive screening of cancer cell lines to identify the most promising candidates for further development.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults and children diagnosed with diffuse large B-cell lymphoma, especially those who have not responded to standard treatments.
Not a fit: Patients with other types of cancers or those who do not have diffuse large B-cell lymphoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a new, effective treatment option for patients with diffuse large B-cell lymphoma, particularly those who have relapsed or are resistant to current therapies.
How similar studies have performed: Previous research has shown success with similar nucleoside analogs in treating hematological cancers, indicating a promising avenue for this novel approach.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Pomerantz, Richard T — Thomas Jefferson University
- Study coordinator: Pomerantz, Richard T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.